Fiche publication
Date publication
janvier 2009
Auteurs
Membres identifiés du Cancéropôle Est :
Pr VELTEN Michel
Tous les auteurs :
Gatta G, Zigon G, Buemi A, Coebergh JW, Colonna M, Contiero P, Denis L, Grosclaude P, Guizard AV, Sanchez-Perez MJ, Plesko I, Ondrusova M, Rachtan J, Valdagni R, Velten M, Vercelli M, Berrino F
Lien Pubmed
Résumé
BACKGROUND: There is wide variation in prostate cancer incidence and survival across Europe. In many countries incidence is rising sharply in relation to the introduction of prostate-specific antigen assay, and there is concern that patients may not be treated appropriately. We therefore aimed to characterize treatment for prostate cancer across Europe. METHODS: We performed a high resolution population-based study, collecting information on the treatment of 3 486 prostate cancer cases diagnosed in 1995-1999 in 11 cancer registries from six European countries. RESULTS: Overall, about one in three patients received radical treatment (prostatectomy 23% or radiotherapy 14%); about 60% of younger patients ( or =70 years) received palliation (transurethral prostatectomy or hormone treatment only). A considerable proportion (61%) of patients with apparently high-risk disease were treated radically within a year of diagnosis, with large variation between regions: >70% in Calvados, Haut-Rhin, Tarn and Eindhoven and
Référence
Acta Oncol. 2009;48(6):867-73.
